Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) CEO James Graham speaks with Proactive after welcoming positive clinical responses to a new gel formulation of its R327® drug candidate, covered by the Therapeutic Goods Administration’s (TGA) Special Access Scheme (SAS). Anecdotal results from two patient case studies are a positive indicator of the gel formulation’s therapeutic potential, while results from an ex vivo burn wound study indicate the R327 gel had the greatest overall efficacy against a strand of antibiotic-resistant bacteria.
Recce is now advancing clinical trial applications to evaluate the R327 gel’s efficacy in common and complicated skin and soft tissue infections in the lab.
Graham said: “Antibiotic resistance is globally recognised as one of the greatest threats to human health today.
“To see Recce making a difference to patients in such great medical need before us, is another welcomed sign of new hope in the fight against drug-resistant superbugs.
“We look forward to building upon these successes among the present and future clinical trials ahead.”
Contact Details
Proactive Investors
Jonathan Jackson
+61 413 713 744
